IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
Chinese Phase 2 biotech developing therapies for T cell-driven inflammatory diseases.
Industry: Health Care
Latest Trade: $1.34 0.00 (0.0%)
First Day Return: +8.8%
Return from IPO: -92.1%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 02/26/2021 |
Offer Price | $17.00 |
Price Range $15.00 - $17.00 | |
Offer Shares (mm) | 11.3 |
Deal Size ($mm) | $191 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 03/18/2021 |
Offer Price | $17.00 |
Price Range $15.00 - $17.00 | |
Offer Shares (mm) | 11.3 |
Deal Size ($mm) | $191 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
Jefferies |
Leerink Partners |
more |
Company Data | |
---|---|
Headquarters | Taicang, China |
Founded | 2012 |
Employees | 62 |
Website www.connectbiopharm.com |